Varenicline and Alcohol in Inpatient Addictions Program (IAP)
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The overall hypothesis of this line of research is that varenicline will decrease alcohol
consumption and tobacco use and will increase alcohol and tobacco abstinence rates. In order
to explore this hypothesis, the investigators will conduct a two-phase study: 1) an open
label pilot study investigating the effect of varenicline on reduction of and abstinence from
alcohol and tobacco; and 2) an optional MR spectroscopy to investigate whether glutamate and
other brain metabolites correlate to measures of alcohol craving severity and/or subsequent
varenicline treatment response.